Close Menu

There's a silver lining to this downturn, and John Browning touches on it in an essay in this week's issue of Nature. "Venture funding is declining quickly and is unlikely to bounce back," he writes. "But less money means lower expectations – good news for smaller science start-ups." While the 1990s boom meant expectations that many companies couldn't meet, today's market gives smaller, less ambitious projects a better chance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.